People who have taken hyped, unregulated peptides have regrets
The Washington Post, publishing KFF Health News reporting, describes people who report symptoms such as fatigue and migraines after taking unapproved peptides such as BPC-157, bought online and labelled not for human use. Their accounts are anecdotal. An FDA advisory panel voted in July to ease restrictions on six experimental peptides against FDA scientists' advice; the FDA has yet to issue a final decision. Promoters often cite animal studies.
Why it matters: Relevant to Maryland adults who come across peptides marketed for injury recovery or weight loss, and to clinicians whose patients ask about unapproved compounds.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to washingtonpost.com. October 13, 2026.
